HOLLY SWENSEN: Open Payments
NPI 1386672012 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$674 in 28 payments from 16 companies in 2025. Trend: 2023 $1,154 · 2024 $2,136 · 2025 $674
Food & beverage: $574Education: $100
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $160 |
| ABBVIE INC. | 3 | $82 |
| E.R. Squibb & Sons, L.L.C. | 5 | $79 |
| Janssen Biotech, Inc. | 2 | $42 |
| Incyte Corporation | 2 | $39 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $30 |
| Genmab U.S., Inc. | 1 | $30 |
| Celgene Corporation | 1 | $30 |
| Rigel Pharmaceuticals, Inc. | 1 | $28 |
| SERVIER PHARMACEUTICALS LLC | 1 | $28 |
Products named: LYNPARZA, EPKINLY, OPDIVO, JAKAFI, Nubeqa, Tivdak, REBLOZYL, IMFINZI.
Industry payments across ID — which companies pay providers there.
